Wayland Group (MRRCF)

[eom7]

Status of File as of February 7, 2020
On February 6, 2020, the Applicants filed a motion (the “Sale Approval Motion”) with the Court for an order (the “Approval and Vesting Order”) to, among other things:

Approve the share purchase agreement (the “Colmed SPA”) entered into on February 2, 2020 by Wayland, as seller, and RG5 Investments Inc. and Albert Sheeler, as buyer (collectively, the “Colmed Buyers”), with respect to the sale of the shares of Wayland’s Colombian subsidiary, Colmed Pharmaceuticals S.A.S. (“Colmed”);
Approve the transactions contemplated by the termination agreement made as of October 11, 2019 (the “Termination Agreement”) among Wayland, Maricann, Maricann B.V. and ICC International Cannabis Corp. (“ICC”) as well as the related Conveyance Agreement (as defined in the Sale Approval Motion);
Postpone Wayland’s annual meeting of shareholders until further order of the Court; and
Approve the fees and activities of the Monitor as described in the Fourth Report of the Monitor, to be filed.
The motion will be heard on February 12, 2020.

https://www.pwc.com/ca/en/services/insolvency-assignments/wayland-group-ltd---nanoleaf-technologies-inc--and-maricann-inc.html